Can solifenacin and tamsulosin be given to a pregnant woman?

Solifenacin and Tamsulosin Should NOT Be Given During Pregnancy

Neither solifenacin nor tamsulosin should be routinely used during pregnancy, though tamsulosin may be considered in specific circumstances during the second and third trimesters when maternal benefit clearly outweighs potential fetal risk.

Solifenacin in Pregnancy

Solifenacin is contraindicated in pregnancy. The FDA drug label clearly states there are no studies in pregnant women to inform drug-associated risk 1. Animal studies demonstrate concerning findings:

• At doses 3.6 times the maximum recommended human dose (MRHD), solifenacin caused:

  • Reduced fetal body weights
  • Maternal toxicity
  • Developmental toxicity 1

• At doses 7.9 times the MRHD, solifenacin caused:

  • Increased incidence of cleft palate
  • Increased maternal lethality 1

• Solifenacin crosses the placental barrier 1

The risk-benefit calculation does not favor solifenacin use in pregnancy. Overactive bladder symptoms, while bothersome, do not represent a life-threatening maternal condition that would justify exposing the fetus to these documented risks. Alternative management strategies (behavioral modifications, pelvic floor therapy) should be prioritized.

Tamsulosin in Pregnancy

Tamsulosin has limited but more reassuring safety data, though it remains FDA Pregnancy Category B with important caveats.

Evidence for Tamsulosin:

The FDA label indicates no evidence of fetal harm in animal studies at doses up to 50 times human exposure 2. However, human data are limited.

Two retrospective studies provide the only human pregnancy data:

• Study 1 (2016): 27 pregnant patients received tamsulosin for symptomatic urolithiasis 3

  • Median exposure: 3 days (range 1-110 days)
  • Exposure occurred across all trimesters
  • No spontaneous abortions, intrauterine deaths, or congenital anomalies
  • No differences in maternal or infant outcomes compared to controls
  • Mean gestational age at delivery: 38.1 weeks

• Study 2 (2020): 69 pregnant patients received tamsulosin 4

  • No significant differences in gestational age, birth weight, or APGAR scores
  • No sudden infant death syndrome cases
  • Stone passage rate: 58% vs 43% in controls (not statistically significant, p=0.18)

Clinical Context for Tamsulosin Use:

The 2026 AUA Guideline on kidney and ureteral stones addresses pregnancy specifically 5:

• Two randomized controlled studies evaluated tamsulosin for stone passage in pregnancy
• Neither study demonstrated significantly improved stone passage rates 5
• Both studies concluded tamsulosin "did not appear to be associated with adverse effects for either mother or unborn child" 5

Critical limitation: Despite safety signals being reassuring, tamsulosin failed to demonstrate efficacy for its intended purpose in pregnant patients.

When Tamsulosin Might Be Considered:

If a pregnant woman has symptomatic urolithiasis and:

• Conservative management (observation, hydration, analgesia) has failed
• She is in the second or third trimester (preferred timing per ACOG recommendations 5)
• Ureteroscopy is declined or unsuccessful
• Symptoms are severe enough to warrant intervention

However, given the lack of proven efficacy and the availability of proven interventions (ureteroscopy, which has demonstrated safety in pregnancy 5), tamsulosin should not be first-line therapy.

Common Pitfalls to Avoid:

1. Do not prescribe solifenacin for overactive bladder in pregnancy - the animal toxicity data and lack of human data make this inappropriate

2. Do not assume tamsulosin is "safe" simply because it's Category B - Category B only means animal studies showed no harm; human data are extremely limited

3. Do not use tamsulosin as first-line for pregnancy urolithiasis - it lacks proven efficacy in this population despite two RCTs 5

4. Do not prescribe these medications in the first trimester - organogenesis occurs during this critical period, and even tamsulosin's limited human data are primarily from second/third trimester exposure 3

5. Do not continue solifenacin if a patient becomes pregnant while taking it - discontinue immediately and counsel regarding potential risks

Practical Algorithm:

For overactive bladder in pregnancy:

• Behavioral modifications (timed voiding, fluid management)
• Pelvic floor physical therapy
• Do NOT use solifenacin

For symptomatic urolithiasis in pregnancy:

1. First-line: Observation with trial of passage (if symptoms controlled) 5
2. Second-line: Ureteroscopy (proven safe, effective intervention) 5
3. Alternative: Nephrostomy tube placement 5
4. Tamsulosin may be considered only if:
   • Second or third trimester
   • Patient declines or cannot undergo ureteroscopy
   • Symptoms warrant intervention beyond conservative management
   • Patient counseled regarding limited efficacy data and limited safety data